This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Portfolio Pulse from Avi Kapoor
Several top Wall Street analysts have downgraded their ratings for notable companies, including Adicet Bio, Novartis, Supernus Pharmaceuticals, and ANI Pharmaceuticals. These downgrades have led to declines in the respective stock prices.
September 11, 2024 | 4:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. downgraded Adicet Bio from Buy to Neutral, causing a 3.4% drop in its stock price.
The downgrade from Buy to Neutral by a reputable analyst firm likely signals reduced confidence in Adicet Bio's near-term prospects, leading to a decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Truist Securities downgraded ANI Pharmaceuticals from Buy to Hold, significantly reducing the price target, resulting in a 5.1% drop in stock price.
The downgrade and substantial cut in price target reflect a negative shift in outlook for ANI Pharmaceuticals, causing a significant drop in its stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90
NEGATIVE IMPACT
B of A Securities downgraded Novartis from Buy to Neutral and lowered the price target, resulting in a 0.2% decrease in stock price.
The downgrade and reduced price target suggest a less optimistic outlook for Novartis, contributing to a slight decline in its stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90
NEGATIVE IMPACT
Piper Sandler downgraded Supernus Pharmaceuticals from Overweight to Neutral, cutting the price target and causing a 1.2% drop in stock price.
The downgrade and lower price target indicate a more cautious stance on Supernus Pharmaceuticals, leading to a decrease in its stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90